Oppenheimer initiated coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $80 price target The firm likes the prospects of the company’s lead asset TX45 to address prevalent and progressive cardiovascular disorders that are inadequately treated. The analyst is optimistic ahead of next year’s Phase 2 readout in pulmonary hypertension with heart failure with preserved ejection fraction, which it believes could pave the way to multi-billion global sales opportunity.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECX:
- Confidence in Tectonic Therapeutic’s Strategic Approach Amid Eli Lilly’s Trial Setback
- Tectonic pullback on Eli Lilly relaxin data ‘overdone,’ says Truist
- Tectonic Therapeutic’s Strategic Expansion and Financial Stability Justify Buy Rating
- Tectonic Therapeutic’s Strategic Advancements and Promising Pipeline Drive Buy Rating
- Promising Outlook for Tectonic Therapeutic: Strategic Differentiation and Market Opportunities